Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody

Leung, Shui-on; Gao, Kai; Wang, Guangyu; Cheung, Benny K. W.; Lee, Kwan-Yeung; Zhao, Qi; Cheung, Wing‐Tai; Wang, Jun Zhi

doi:10.4161/19420862.2014.985519

Cited by 3 publications

(2 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade effective methods for clinical grade purification and expansion of donor NK cells from PB and PBSC have been established successfully in order to obtain large numbers of NK cells ( Iyengar et al, 2003 ; Koehl et al, 2005 , 2013 ; Miller et al, 2005 ; Sutlu et al, 2010 ; Leung, 2011 ; Leung et al, 2014 ). In this respect, feasibility and safety of NK cell therapies has been shown in several phase I/II trials performing both the adoptive transfer of donor NK cells without transplantation ( Miller et al, 2005 ) or donor-derived allogeneic NK cells post-SCT ( Koehl et al, 2004 ; Stern et al, 2013 ; Leung et al, 2014 ). Depending on the source and the protocol, more immature, such as polyfunctional CD56 dim KIR + CD62L + or mature terminal effector CD56 dim KIR + NKG2A - CD62L - NK cells are available for the use in clinical studies ( Luetke-Eversloh et al, 2013 ).…”

Section: Nk Cell Sourcesmentioning

confidence: 99%

Advantages and applications of CAR-expressing natural killer cells

et al. 2015

View full text Add to dashboard Cite

In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against resistant cancer cells, auspicious efforts have been made with chimeric antigen receptor (CAR) expressing T- and NK cells. These CAR-modified cells express antigen receptors against tumor-associated surface antigens, thus redirecting the effector cells and enhancing tumor-specific immunosurveillance. However, many cancer antigens are also expressed on healthy tissues, potentially leading to off tumor/on target toxicity by CAR-engineered cells. In order to control such potentially severe side effects, the insertion of suicide genes into CAR-modified effectors can provide a means for efficient depletion of these cells. While CAR-expressing T cells have entered successfully clinical trials, experience with CAR-engineered NK cells is mainly restricted to pre-clinical investigations and predominantly to NK cell lines. In this review we summarize the data on CAR expressing NK cells focusing on the possible advantage using these short-lived effector cells and discuss the necessity of suicide switches. Furthermore, we address the compliance of such modified NK cells with regulatory requirements as a new field in cellular immunotherapy.

show abstract

Section: Nk Cell Sourcesmentioning

confidence: 99%

Advantages and applications of CAR-expressing natural killer cells

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Because anti-CD22 mAbs can target and suppress matured B cells, their indications have been further expanded for the treatment of rheumatoid arthritis (RA), systemic lupus erythematous (SLE), etc. Therefore, it is urgently necessary to develop consistent and reliable protocols for quality control (QC) analysis of anti-CD22 mAbs and derivatives during antibody production or clinical studies [ 12 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method

Zhao

2022

Antibodies

Self Cite

View full text Add to dashboard Cite

Since they lack native soluble membrane antigens, the analysis and selection of antigen-specific antibodies are commonly performed on whole live cells. Here, we have developed a simple and convenient enzyme-linked immunosorbent assay (ELISA) based on cell membrane antigens. Soluble cell membrane proteins isolated from Raji cells were immobilized on the polystyrene microplate, which permitted the assessment of a therapeutic anti-CD22 monoclonal antibody. The experiments showed less variability in the intra-assay. Compared to the living cell ELISAs, the advantage of the assay is avoiding cell losses and high variation of optical density (OD) readings. We provide a quantitative and reproducible ELISA that can be potentially applied to the development of specific antibodies against cell surface antigens.

show abstract

Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus

Zhao

Chen

et al. 2016

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody

Abstract: (2015) Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody, mAbs, 7:1, 66-76,

Cited by 3 publications

References 35 publications

Advantages and applications of CAR-expressing natural killer cells

Advantages and applications of CAR-expressing natural killer cells

Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method

Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About